Abbott Laboratories

ticker: ABT step: 01 generated: 2026-05-12 source: quick-research

Abbott Laboratories (ABT) — Business Overview

Business Description

Abbott Laboratories is a diversified healthcare company operating across four segments: Medical Devices (45% of revenue), Nutrition (22%), Diagnostics (20%), and Established Pharmaceuticals (13%). The portfolio anchored by FreeStyle Libre (#1 global continuous glucose monitor — $7B+ run rate growing 20%+) and structural heart franchise (MitraClip, TriClip, Amplatzer Amulet). The March 2026 close of the $20B+ Exact Sciences acquisition adds high-growth cancer diagnostics. Robert Ford is CEO.

Revenue Model

• Medical Devices (~45% of revenue): Diabetes (FreeStyle Libre CGM + Lingo consumer biosensor), Cardiovascular (Coronary, Structural Heart, Heart Failure, Vascular), Neuromodulation, Rhythm Management (AVEIR leadless pacemakers, Volt PFA)
• Nutrition (~22%): Pediatric (Similac, PediaSure), Adult (Ensure, Glucerna), International nutrition
• Diagnostics (~20%): Core Lab (Alinity), Molecular (m2000, Alinity m), Rapid Diagnostics, Point of Care (post-Exact Sciences: cancer screening)
• Established Pharmaceuticals (EPD, ~13%): Branded generics primarily in emerging markets (India, Latin America, China, Russia, etc.)

Products & Services

Medical Devices

• FreeStyle Libre family: Libre 2 Plus, Libre 3 Plus, Libre 4 (under development), Lingo consumer wellness biosensor — #1 CGM globally
• Cardiovascular: XIENCE coronary stents, MitraClip + TriClip (transcatheter heart valves), Amplatzer Amulet (LAA closure), Navitor, HeartMate (heart failure)
• Rhythm Management: AVEIR leadless pacemakers (single + dual-chamber), Volt PFA (pulsed field ablation, FDA approved Dec 22, 2025)
• Vascular: XIENCE PRO, Esprit BTK
• Neuromodulation: Spinal cord stim, deep brain stim, dorsal root ganglion

Diagnostics

• Alinity: Integrated lab platform
• m2000 / Alinity m: Molecular (PCR)
• Rapid Diagnostics: BinaxNOW, ID Now
• Exact Sciences (March 2026): Cologuard (colorectal cancer screening), Oncotype DX

Nutrition

• Pediatric: Similac infant formula, PediaSure, Pedialyte
• Adult: Ensure, Glucerna, ZonePerfect
• International nutrition (high growth in EM)

Established Pharmaceuticals

• Branded generics in ~15 emerging markets
• Cardiology, hepatology, gastroenterology, women's health franchises

Customer Base & Go-to-Market

• Patients: Billions globally — Libre alone has ~6M users, Cologuard 4M+ tests annually
• Physicians + Hospitals: Cardiologists, electrophysiologists, endocrinologists, OB-GYN, primary care
• Pharmacies + retailers: Nutrition products through grocery + drug + Amazon
• Public sector: WIC + global infant nutrition programs
• Geographic mix: ~40% International, ~60% US

Competitive Position

Abbott has multiple #1 or #2 positions in major franchises: #1 in CGM (Libre vs Dexcom G7), #1 in heart valve replacement via MitraClip, #1 nutritional products company globally. Moats: (1) Libre cost-efficient CGM strategy (lower price + broader access vs Dexcom premium), (2) MitraClip first-mover advantage in TEER market, (3) AVEIR dual-chamber leadless pacemaker first to market, (4) Exact Sciences Cologuard franchise dominant in colorectal screening. Faces (1) Dexcom in CGM (especially G8/Stelo), (2) Boston Scientific in PFA + electrophysiology, (3) Medtronic broadly across devices.

Key Facts

• Founded: 1888 (Wallace C. Abbott)
• Headquarters: Abbott Park, IL
• Employees: ~115,000
• Exchange: NYSE
• Sector / Industry: Health Care / Medical Devices + Diagnostics + Nutrition
• Market Cap: ~$215B (May 2026)
• CEO: Robert B. Ford (since 2020)
• Dividend: $2.36 annual ($0.59 quarterly)
• 52 consecutive years of dividend growth (Dividend King)
• Major M&A: Exact Sciences $20B+ (closed March 2026); legacy: AbbVie spin-off 2013, St. Jude Medical $25B 2017

ticker: ABT step: 04 generated: 2026-05-12 source: quick-research

Abbott Laboratories (ABT) — Financial Snapshot

Income Statement Summary

Segment Revenue (FY2025)

Q1 2026 Highlights

Key Product Metrics

Cash Flow & Balance Sheet (FY2025)

Key Ratios (approximate, May 2026)

• P/E (forward): ~24x | EV/EBITDA: ~17x | Dividend Yield: ~2.0%
• ROIC: ~14% (will dip on Exact Sciences integration before accretion)
• FCF Margin: ~16%
• Net Debt/EBITDA: ~3x post-Exact Sciences (elevated near-term)

Growth Profile

FY26 sales outlook: 6.5-7.5% comparable growth. Medical Devices is the primary growth engine (especially Libre + Volt PFA + AVEIR). Q1 2026 saw Libre annualizing to $8.3B run rate. Exact Sciences ($3B incremental revenue 2026, growing high-teens) adds to Diagnostics. Bear-case overhang: FreeStyle Libre 3/3 Plus recall (3M units, FDA Class I, 860 serious injuries + 7 deaths) plus nutrition softness.

Forward Estimates

• FY2026E Revenue: ~$50B (incl. Exact Sciences full year)
• FY2026E Adj EPS: $5.05-5.25 (mgmt guide; +6-8%)
• FY2027E EPS: ~$5.85 (+12-15%)
• FY2028E Libre revenue target: $10B+ (vs $7B in 2025)

Capital Return

• Dividend $2.36 annual (~$4B paid)
• 52 consecutive years of dividend growth (Dividend King)
• Buybacks: ~$2-3B annual run rate, moderated post-Exact Sciences debt paydown priority
• Total return: ~3-4% combined yield + 10%+ EPS growth

ticker: ABT step: 12 generated: 2026-05-12 source: quick-research

Abbott Laboratories (ABT) — Investment Catalysts & Risks

Bull Case Drivers

1. FreeStyle Libre on track to $10B by 2028 — Q1 2026 Diabetes Care revenue annualized to $8.3B. Management's 2028 target of $10B Libre revenue requires only ~10% annual growth from here — below the 13.8% segment growth just posted. Lingo consumer biosensor extends Libre franchise into wellness/fitness market (not just diagnosed diabetics). New Libre 4 generation in development could re-accelerate growth.

2. Volt PFA + AVEIR drive Cardiovascular acceleration — December 22, 2025 FDA approval of Volt pulsed field ablation puts Abbott in fastest-growing atrial fibrillation treatment category. PFA expected to take most of the $6B US cardiac ablation market from older RF approaches by 2028. AVEIR dual-chamber leadless pacemaker drove Rhythm Management +17% in Q1 2026. Combined, these can offset slower segments.

3. Exact Sciences acquisition adds $3B+ growing high-teens — March 2026 close of $20B+ Exact Sciences deal adds Cologuard (colorectal cancer screening) franchise — the dominant player in colorectal screening with 80%+ market share. $3B incremental revenue 2026, growing high teens. Creates a $12B+ diagnostics platform.

4. 52-year Dividend King + recovery setup post 17% YTD decline — Stock down ~17% YTD on Libre recall + Exact Sciences debt funding + nutrition weakness. 15 of 17 analysts rate Buy/Strong Buy; consensus 12-month target $134.29 (~40% upside). 52 consecutive dividend increases. Combination of catalysts (recall resolution, Volt PFA ramp, Exact Sciences integration) creates a multi-year compounding setup.

Bear Case Risks

1. FreeStyle Libre 3/3 Plus recall — FDA Class I, 7 deaths reported — FDA linked 860 serious injuries + 7 deaths to faulty glucose readings from certain Libre 3 / Libre 3 Plus sensors. Recall affected ~3 million units. Bear case: slower remediation, ongoing class action litigation, regulatory scrutiny could materially impact Libre growth + brand. Diabetes Care growth slowed to 7.5% in Q1 2026 (from ~20%+ pace prior to recall).

2. Exact Sciences integration risk + $20B new debt — $20B in new debt to fund Exact Sciences raises interest costs and integration risk. Deal not accretive until 2028. Net debt/EBITDA jumps to ~3x — elevated for Abbott. Integration of large standalone company has historical mixed results (St. Jude Medical 2017 integration was bumpy initially).

3. Nutrition segment chronic weakness — Nutrition revenue -8.9% in Q4 2025; -2% full year. Volume weakness + pricing actions. The infant formula crisis (Sturgis, MI plant 2022) still casts a shadow. Nutrition has historically been a stable margin contributor; persistent weakness offsets Medical Devices strength.

4. CGM competitive + reimbursement pressure — Dexcom G7 / G8 + Stelo over-the-counter CGM competing with Libre. US competitive bidding for CGMs (proposed in Medicare) could compress Libre pricing. Outside US, single-payer healthcare systems negotiating aggressively.

Upcoming Events

• Q2 2026 earnings (July 2026) — Libre recall resolution; Exact Sciences integration milestones; Volt PFA early commercial trajectory
• FDA Libre 4 submission/approval — Next-gen CGM platform
• Volt PFA commercial ramp — Critical for Cardiovascular acceleration narrative
• Annual investor day — Multi-year algorithm update
• Exact Sciences accretion milestones — Target 2028 EPS accretion

Analyst Sentiment

Sell-side consensus is Buy / Strong Buy — 15 of 17 analysts rate Buy/Strong Buy with zero Sell ratings. Average price targets cluster at $130-140 vs. recent ~$120 (post 17% YTD decline) — ~10-20% upside. Bulls cite Libre trajectory to $10B, Volt PFA + AVEIR catalysts, Exact Sciences platform, and 52-year dividend track record. Bears focus on Libre recall, integration debt, and nutrition weakness.

Research Date

Generated: 2026-05-12